search
Back to results

The Adverse Drug Reaction (ADRe) Profile for Polypharmacy (ADRe-p)

Primary Purpose

Polypharmacy

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Adverse Drug Reaction ADRe Profile for Polypharmacy
Sponsored by
Swansea University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Polypharmacy focused on measuring medicines management, adverse drug reaction, care homes, nurses

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • • Resident at the care home and expected to continue to live there for 1 year

    • Currently taking >3 prescribed medicines daily
    • Willing and able to give informed, signed consent themselves, or where capacity is lacking, a consultee is willing to give advice and assent to the resident participating.

Exclusion Criteria:

  • age <18

    • Prescribed <4 medicines daily;
    • Receiving active palliative care
    • Not well enough to participate, as screened by their nurses

Sites / Locations

  • Swansea University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

intervention

Arm Description

This is a single arm before and after study with data collection at 4 time points.

Outcomes

Primary Outcome Measures

Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents
Number of participant with a change in signs and symptoms related to adverse effects of prescribed medicines. Care quality/ clinical gain/ benefit to patients as recorded in notes and on the Profile by the number and nature of all health problems addressed, particularly serious adverse events.

Secondary Outcome Measures

Number of Clinical Gains Per Resident Between Baseline and 3 Months
Number of problems addressed or ameliorated per resident e.g. pain, falls, sedation. Number at baseline minus number at 3 months.
Number of Medicines Prescribed: Change Between Baseline and 3 Months
number of medicines prescribed, including all prescription items, supplements and topical preparations. change in number during the intervention period (baseline minus 3 months)
Number of Problems Listed on Profile
Number of problems listed on the ADRe-p profile per resident. All problems might be attributable to prescribed medicines. Change in number.

Full Information

First Posted
May 15, 2019
Last Updated
August 16, 2021
Sponsor
Swansea University
Collaborators
Aneurin Bevan University Health Board, Cardiff University
search

1. Study Identification

Unique Protocol Identification Number
NCT03955133
Brief Title
The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Acronym
ADRe-p
Official Title
Polypharmacy and Adverse Drug Reactions: Nurse-led Intervention to Minimise Adverse Drug Reactions for Older Adults in Care Homes: a Quality Improvement Process Intervention
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
December 18, 2018 (Actual)
Primary Completion Date
May 31, 2019 (Actual)
Study Completion Date
December 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Swansea University
Collaborators
Aneurin Bevan University Health Board, Cardiff University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Polypharmacy, the use of multiple or inappropriate medications, has the potential to harm older adults by causing cognitive impairment, falls, and hospitalisations. The nurse-led intervention (The ADRe Profile) to review mental health medicines has demonstrated improved care quality by: identifying serious adverse drug reactions (ADRs); reducing prescription of mental health medicines; reducing the prevalence of pain and nausea; and, increasing non-urgent national health service (NHS) contacts. The investigators will develop ADRe to encompass medicines commonly prescribed in primary care and evaluate intervention implementation in care homes in Aneurin Bevan University Health Board.
Detailed Description
The investigators will introduce medicines' monitoring using the PADRe Profile into up to 7 care homes, each with up to 26 residents prescribed >4 medicines (estimated ~90% residents). Each home will identify a nurse lead and a deputy. Nurses will be asked to administer the PADRe Profile with all patients prescribed >4 medicines. Barriers, facilitators, and feasibility of the Profile will be explored. This will identify how, in which contexts medicines' monitoring can be integrated into routine care, relate the Profile to improved processes and outcomes of care, and inform implementation strategies (see logic model in cited papers). Data collection: Record review before and after each of 3 administrations of the intervention to identify clinical and prescription changes. Narrative accounts of problems causing moderate or severe harm will be prepared. Serial interviews and debriefs with nurses: three per nurse. Stakeholder interviews with patients, participating pharmacists and prescribers for an overview of implementation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Polypharmacy
Keywords
medicines management, adverse drug reaction, care homes, nurses

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All participating care homes will receive the intervention at the same time. Residents' records and medicines charts will be reviewed sequentially.
Masking
None (Open Label)
Masking Description
Use of the intervention could not be blinded.
Allocation
N/A
Enrollment
19 (Actual)

8. Arms, Groups, and Interventions

Arm Title
intervention
Arm Type
Experimental
Arm Description
This is a single arm before and after study with data collection at 4 time points.
Intervention Type
Other
Intervention Name(s)
Adverse Drug Reaction ADRe Profile for Polypharmacy
Intervention Description
PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the British National Formulary (BNF) and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
Primary Outcome Measure Information:
Title
Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents
Description
Number of participant with a change in signs and symptoms related to adverse effects of prescribed medicines. Care quality/ clinical gain/ benefit to patients as recorded in notes and on the Profile by the number and nature of all health problems addressed, particularly serious adverse events.
Time Frame
3 months from start of intervention
Secondary Outcome Measure Information:
Title
Number of Clinical Gains Per Resident Between Baseline and 3 Months
Description
Number of problems addressed or ameliorated per resident e.g. pain, falls, sedation. Number at baseline minus number at 3 months.
Time Frame
Baseline, then 3 months from start of intervention
Title
Number of Medicines Prescribed: Change Between Baseline and 3 Months
Description
number of medicines prescribed, including all prescription items, supplements and topical preparations. change in number during the intervention period (baseline minus 3 months)
Time Frame
Baseline, then 3 months from start of intervention
Title
Number of Problems Listed on Profile
Description
Number of problems listed on the ADRe-p profile per resident. All problems might be attributable to prescribed medicines. Change in number.
Time Frame
Baseline, then 3 months from start of intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Resident at the care home and expected to continue to live there for 1 year Currently taking >3 prescribed medicines daily Willing and able to give informed, signed consent themselves, or where capacity is lacking, a consultee is willing to give advice and assent to the resident participating. Exclusion Criteria: age <18 Prescribed <4 medicines daily; Receiving active palliative care Not well enough to participate, as screened by their nurses
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
sue jordan, PhD
Organizational Affiliation
Swansea University
Official's Role
Study Chair
Facility Information:
Facility Name
Swansea University
City
Swansea
ZIP/Postal Code
sa2 8pp
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
The terms of our ethical approval would not allow this.
Citations:
PubMed Identifier
30231573
Citation
Jordan S, Logan PA, Panes G, Vaismoradi M, Hughes D. Adverse Drug Reactions, Power, Harm Reduction, Regulation and the ADRe Profiles. Pharmacy (Basel). 2018 Sep 18;6(3):102. doi: 10.3390/pharmacy6030102.
Results Reference
background
PubMed Identifier
30269073
Citation
Jordan S, Banner T, Gabe-Walters M, Mikhail JM, Round J, Snelgrove S, Storey M, Wilson D, Hughes D; Medicines Management Group. Nurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines. BMJ Open. 2018 Sep 28;8(9):e023377. doi: 10.1136/bmjopen-2018-023377.
Results Reference
background
PubMed Identifier
33411824
Citation
Jordan S, Prout H, Carter N, Dicomidis J, Hayes J, Round J, Carson-Stevens A. Nobody ever questions-Polypharmacy in care homes: A mixed methods evaluation of a multidisciplinary medicines optimisation initiative. PLoS One. 2021 Jan 7;16(1):e0244519. doi: 10.1371/journal.pone.0244519. eCollection 2021.
Results Reference
result

Learn more about this trial

The Adverse Drug Reaction (ADRe) Profile for Polypharmacy

We'll reach out to this number within 24 hrs